Muromonab
Identification
- Summary
Muromonab is a monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
- Generic Name
- Muromonab
- DrugBank Accession Number
- DB00075
- Background
Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Structure
- Protein Chemical Formula
- C6460H9946N1720O2043S56
- Protein Average Weight
- 146189.7 Da
- Sequences
>Muromonab-CD3 light chain QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAH FRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINRADTAPTVSIFPPS SEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTL TKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
>Muromonab-CD3 heavy chain QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNY NQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSA KTTAPSVYPLAPVCGGTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Download FASTA Format- Synonyms
- Anti-CD3
- Muromonab-CD3
Pharmacology
- Indication
For treatment of organ transplant recipients, prevention of organ rejection
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Acute renal allograft rejection •••••••••••• ••••••••• Management of Steroid resistant heart transplant rejection •••••••••••• ••••••••• Management of Steroid resistant hepatic transplant rejection •••••••••••• ••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Used in organ transplant prophylaxis, Muromonab or OKT-3 binds specifically to the CD-3 complex, which is involved in antigen recognition and cell stimulation, on the surface of T lymphocytes. Immediately after administration CD-3-positive T lymphocytes are abruptly removed from circulation. It has been effective in reversing corticosteroid-resistant acute rejection in renal, liver, and cardiac transplant recipients.
- Mechanism of action
Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.
Target Actions Organism AT-cell surface glycoprotein CD3 delta chain Not Available Humans AT-cell surface glycoprotein CD3 epsilon chain binderHumans AT-cell surface glycoprotein CD3 gamma chain Not Available Humans AT-cell surface glycoprotein CD3 zeta chain Not Available Humans ULow affinity immunoglobulin gamma Fc region receptor III-B Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production
- Route of elimination
Not Available
- Half-life
0.8 hours (mammalian reticulocytes, in vitro)
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The risk or severity of adverse effects can be increased when Muromonab is combined with Abatacept. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Muromonab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Muromonab. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Muromonab. Aducanumab The risk or severity of adverse effects can be increased when Muromonab is combined with Aducanumab. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Orthoclone OKT3 (Janssen-Cilag)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Okt3 Injection, solution 5 mg/5mL Intravenous Centocor Ortho Biotech Products, L.P. 1986-07-19 2011-07-30 US Orthoclone Okt 3 Sterile Solution IV 1mg/ml Solution 1 mg / mL Intravenous Janssen Pharmaceuticals 1987-12-31 2007-07-09 Canada
Categories
- ATC Codes
- L04AA02 — Muromonab-cd3
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic and Immunomodulating Agents
- Blood Proteins
- CD3 Blocker Immunosuppressant
- CD3 Receptor Antagonists
- CD3-directed Antibody Interactions
- Decreased Immunologic Activity
- Globulins
- Immunoglobulin G
- Immunoglobulin Isotypes
- Immunoglobulins
- Immunologic Factors
- Immunoproteins
- Immunosuppressive Agents
- Proteins
- Selective Immunosuppressants
- Serum Globulins
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- JGA39ICE2V
- CAS number
- 140608-64-6
References
- General References
- Not Available
- External Links
- KEGG Drug
- D05092
- PubChem Substance
- 46507837
- 42405
- ChEMBL
- CHEMBL1201608
- Therapeutic Targets Database
- DAP001301
- PharmGKB
- PA164743097
- Wikipedia
- Muromonab-CD3
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative 1 3 Active Not Recruiting Treatment Recurrent B Acute Lymphoblastic Leukemia 1 3 Completed Treatment Type 1 Diabetes Mellitus 2 3 Not Yet Recruiting Treatment B-cell Acute Lymphoblastic Leukemia 1 3 Recruiting Treatment B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Centocor Ortho Biotech Inc.
- Dosage Forms
Form Route Strength Injection, solution Intravenous 5 mg/5mL Solution Intravenous 1 mg / mL - Prices
Unit description Cost Unit Orthoclone okt-3 5 mg/5 ml 261.75USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 61 °C (FAB fragment), 71 °C (whole mAb) Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000) hydrophobicity -0.513 Not Available isoelectric point 8.31 Not Available
Targets
![](https://go.drugbank.com/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png)
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- General Function
- Transmembrane signaling receptor activity
- Specific Function
- The CD3 complex mediates signal transduction.
- Gene Name
- CD3D
- Uniprot ID
- P04234
- Uniprot Name
- T-cell surface glycoprotein CD3 delta chain
- Molecular Weight
- 18929.38 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Binder
- General Function
- Transmembrane signaling receptor activity
- Specific Function
- The CD3 complex mediates signal transduction, resulting in T cell activation and proliferation. Required for normal immune responses (PubMed:15546002, PubMed:8490660).
- Gene Name
- CD3E
- Uniprot ID
- P07766
- Uniprot Name
- T-cell surface glycoprotein CD3 epsilon chain
- Molecular Weight
- 23147.09 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- General Function
- Transmembrane signaling receptor activity
- Specific Function
- The CD3 complex mediates signal transduction.
- Gene Name
- CD3G
- Uniprot ID
- P09693
- Uniprot Name
- T-cell surface glycoprotein CD3 gamma chain
- Molecular Weight
- 20469.335 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- General Function
- Transmembrane signaling receptor activity
- Specific Function
- Probable role in assembly and expression of the TCR complex as well as signal transduction upon antigen triggering.
- Gene Name
- CD247
- Uniprot ID
- P20963
- Uniprot Name
- T-cell surface glycoprotein CD3 zeta chain
- Molecular Weight
- 18696.275 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent...
- Gene Name
- FCGR3B
- Uniprot ID
- O75015
- Uniprot Name
- Low affinity immunoglobulin gamma Fc region receptor III-B
- Molecular Weight
- 26215.64 Da
References
- Pellegrini P, Berghella AM, Del Beato T, Adorno D, Casciani CU: Immunological directives for biotherapy improvement in the treatment of colorectal cancer. Cancer Biother Radiopharm. 1996 Apr;11(2):113-8. [Article]
- Contasta I, Pellegrini P, Berghella AM, Del Beato T, Canossi A, Di Rocco M, Adorno D, Casciani CU: Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer. Cancer Biother Radiopharm. 1996 Dec;11(6):373-83. [Article]
Drug created at June 13, 2005 13:24 / Updated at January 02, 2024 23:41